MétaCan
Menu
← Back to cohort

Clinical and Genetic Determinants of Tacrolimus Dose During Induction and Stable Phase of Therapy.

2014· article· en· W2772351506 on OpenAlexaff
Inna Y. Gong, Maxwell Edgar, Sarah Langford, Ute I. Schwarz, Rommel G. Tirona, Anthony M. Jevnikar, Norman Muirhead, R. Kim

Bibliographic record

VenueTransplantation · 2014
Typearticle
Languageen
FieldMedicine
TopicRenal Transplantation Outcomes and Treatments
Canadian institutionsWestern University
Fundersnot available
KeywordsTacrolimusCalcineurinMedicineCYP3A5DosingTrough levelPharmacologyCYP3AInternal medicineTransplantationUrologyGenotypeBiologyMetabolismCytochrome P450

Abstract

fetched live from OpenAlex

Background Tacrolimus is a calcineurin inhibitor widely used in patients undergoing solid organ transplantation. However, tacrolimus therapy is hindered by highly variable dose requirements in patients associated with toxicity and efficacy (prevention of rejection). Metabolism of tacrolimus via the cytochrome P450 (CYP) 3A family accounts for a significant portion of tacrolimus dosing requirements. Currently, there is paucity of data regarding predictors of tacrolimus dosing, particularly during the initiation (induction) phase of therapy. Thus, we assessed the differential impact of CYP3A genetic polymorphisms on tacrolimus dose and plasma exposure during induction and maintenance phases of therapy. Methods We enrolled 167 renal transplant patients treated with tacrolimus (as bid Prograf) who were at least 3 months post-transplant. Tacrolimus trough concentrations and dose adjustments during induction (0 - 3 months) and stable phase (after 3 months) were retrospectively analyzed. Results The mean tacrolimus dose required during both induction and stable phase was significantly greater in CYP3A5 expressors (CYP3A5*1/*1 and *1/*3) compared to non-expressors (CYP3A5*3/*3; P<0.0001). Importantly, dose-normalized trough concentrations were significantly lower for CYP3A5 expressors (P<0.0001). In addition, dose-normalized concentrations appeared to be consistent throughout the treatment periods, indicating that intrinsic metabolism of tacrolimus does not vary between induction and stable phase of therapy. Regression analysis indicated that CYP3A5*3 and CYP3A4*22 genotype, hemoglobin, and weight were significant predictors of induction dose, accounting for 30% of the variation, while CYP3A5*3 genotype, months post transplant, and age were significant predictors of stable dose, accounting for 42% of the variation. Other significant variables with less impact on tacrolimus dose include POR*28, ABCB1 3435C>T, PXR -25385C>T, and creatinine clearance. Conclusions We demonstrated that CYP3A5*3 genotype is the major determinant of tacrolimus dose variability during induction and stable therapy. Genetic variation in CYP3A4 (*22) was identified as yet unrecognized significant contributor to tacrolimus dose. These findings have the potential to individualize tacrolimus dosing, reduce time to target concentration, improve efficacy, and minimize toxicities. DISCLOSURES:Muirhead, N.: Grant/Research Support, Astella. Kim, R.: Grant/Research Support, Astella.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.045
GPT teacher head0.368
Teacher spread0.323 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes1
Has abstractyes

Explore more

Same venueTransplantation→Same topicRenal Transplantation Outcomes and Treatments→French-language works237,207→